Skip to content
    MO
    Earnings call· Dec 2025(Q4 FY25)

    ALTRIA GROUP, INC. MO

    Jan 29, 2026 Source

    Executive summary

    Altria Group Q4 FY25 — Strong Financials & Smoke-Free Progress Amidst Regulatory Headwinds

    Altria delivered strong full-year financial results and advanced its smoke-free portfolio in 2025, marked by key regulatory authorizations and strategic collaborations. Despite ongoing challenges from illicit e-vapor products and competitive pressures in nicotine pouches, the company is focused on national expansion of on! PLUS and continued investment in its smoke-free vision, while navigating a dynamic regulatory landscape.

    Highlights

    5
    • Adjusted diluted EPS grew by 4.4% for the full year 2025.

    • Returned $8 billion to shareholders through dividends and share repurchases in 2025.

    • Smokeable Products segment delivered over $11 billion in adjusted OCI for FY25, expanding margins by 1.8 percentage points to 63.4%.

    • on! reported shipment volume grew by approximately 11% to more than 177 million cans for the full year 2025.

    • Middleton reported shipment volume increased 4.2% in Q4 and 1.8% for the full year, outperforming the mass cigar industry.

    Concerns

    5
    • Smokeable Products segment adjusted OCI declined by 2.4% in Q4, with margins contracting by 0.8 percentage points to 60.4%.

    • Domestic cigarette volumes declined by 7.9% in Q4 and 10% for the full year 2025.

    • Marlboro's retail share declined 1.5 share points in Q4 and 1.2 share points for the full year.

    • Oral Tobacco Products segment adjusted OCI declined by 4.6% in Q4, with margins contracting by 5 percentage points to 64.5%.

    • Recorded noncash impairment charges of $1.3 billion related to e-vapor definite-lived intangible assets and goodwill due to slower-than-expected enforcement against illicit products.

    Guidance & targets

    3
    CategoryTargetConfidence
    Adjusted diluted EPS
    $5.56 to $5.72
    high materiality
    High
    Adjusted diluted EPS growth rate
    2.5% to 5.5%
    high materiality
    High
    Helix profitability
    profitable
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Smokeable Products
    The Smokeable Products segment delivered strong full-year adjusted OCI and margin expansion, but experienced a decline in Q4 adjusted OCI and margins. Domestic cigarette volumes continued to decline, with Marlboro losing retail share while Basic gained share, reflecting a strategy to compete in price-sensitive segments. Middleton cigars continued to outperform the industry.
    Adjusted OCI (FY25): >$11BAdjusted OCI margin expansion (FY25): 1.8 percentage pointsAdjusted OCI (Q4): -2.4%Adjusted OCI margin (Q4): 60.4%Adjusted OCI margin contraction (Q4): 0.8 percentage pointsDomestic cigarette volumes (Q4): -7.9%Domestic cigarette volumes (FY25): -10%Domestic cigarette volumes adjusted (Q4): -7%Domestic cigarette volumes adjusted (FY25): -9.5%Marlboro retail share (Q4): -1.5 share pointsMarlboro retail share (FY25): -1.2 share pointsMarlboro share premium (Q4): 59.2%Marlboro share premium contraction (Q4): 0.1 share pointsMarlboro share (FY25): 59.4%Marlboro share growth (FY25): 0.1 share pointsBasic retail share growth (Q4 sequential): 0.6 share pointsBasic retail share growth (Q4 YoY): 1.9 share pointsMiddleton reported shipment volume (Q4): +4.2%Middleton reported shipment volume (FY25): +1.8%
    63.4%
    Oral Tobacco Products
    The Oral Tobacco Products segment saw a decline in adjusted OCI and margins in Q4 due to strategic investments in on! and on! PLUS. Full-year adjusted OCI increased modestly. Total shipment volume decreased, as growth in on! was offset by lower MST volumes. on! maintained its retail share despite competitive promotional activity.
    Adjusted OCI (Q4): -4.6%Adjusted OCI margin contraction (Q4): 5 percentage pointsAdjusted OCI (FY25): +1.3%Adjusted OCI margin expansion (FY25): 0.1 percentage pointsTotal segment reported shipment volume (Q4): -6.3%Total segment reported shipment volume (FY25): -5.5%Total segment reported shipment volume adjusted (Q4): -6%Total segment reported shipment volume adjusted (FY25): -4.5%on! reported shipment volume (FY25): +11%on! reported shipment volume (Q4): >44M canson! reported shipment volume (FY25): >177M canson! retail share (Q4): 7.7%on! retail share (FY25): 8.2%Oral Tobacco Products segment retail share (Q4): 29.6%Oral Tobacco Products segment retail share (FY25): 31.9%
    64.5%

    Operational metrics

    26
    Adjusted diluted EPS growth
    4.4%YoY
    FY25

    For the full year 2025.

    Shareholder returns
    $8B
    FY25

    Combined dividends and share repurchases.

    Adult consumers in e-vapor and oral tobacco categories
    almost 30M
    2025

    Estimated number, nearly as large as the adult smoker population.

    Total nicotine industry equivalized volumes growth
    2%CAGR
    past 5 years

    Compounded annual growth rate.

    Smoke-free alternatives share of total nicotine space
    50%up 5 percentage points
    2025

    Estimated share, up from prior year.

    E-vapor category growth
    15%
    2025

    Estimated growth.

    Illicit products share of e-vapor category
    70%
    2025

    Estimated share.

    Vapors count
    >20M
    year-end 2025

    Estimated total vapors.

    Disposable vapors count
    nearly 15M
    year-end 2025

    Estimated users of disposable products.

    Disposable e-vapor volumes growth
    30%vs >50% in 2024
    2025

    Growth moderated compared to prior year.

    Disposable vapors count growth
    10%vs >40% in 2024
    2025

    Growth in number of disposable vapors slowed.

    FDA tobacco user fees for enforcement
    $200M
    Q4 2025 legislation

    Minimum allocation required by legislation.

    Oral tobacco volume growth
    14%
    past 6 months

    Estimated growth.

    Nicotine pouches share of total oral category
    57%up 10.4 share points YoY
    Q4

    Represents nearly 57% of the total oral category.

    Competitive nicotine pouch average retail prices
    -3%sequential
    Q4

    For category competitors, reflecting elevated promotional activity.

    on! average retail price
    +4%sequential
    Q4

    Helix focused on balancing profitability with retaining loyal consumers.

    Basic retail share
    +0.6 share pointssequential
    Q4

    Basic continued to capture share in the discount segment.

    Discount retail share growth
    2.6 share points
    Q4

    Persistent discretionary income pressures remained the primary driver of growth.

    Cigarette industry decline rate cross-category impact
    2% to 3%vs prior estimate of 3% to 4%
    past 12 months

    Updated estimate based on latest data, showing moderation.

    Impairment charges
    $1.3B
    Q4

    Due to slower-than-expected effective enforcement against illicit e-vapor volumes.

    Dividends paid
    $7B
    FY25

    Paid to shareholders.

    Dividend increase
    3.9%
    August

    Board raised dividend.

    Share repurchases
    $1B
    FY25

    Under current share repurchase program.

    Total debt-to-EBITDA ratio
    2x
    Dec 31

    In line with target.

    Cost per pack comparison
    Q4

    Impacted by higher manufacturing costs driven by investments to build PM USA cigarette import and export capabilities.

    Return on investment for import export
    very strong
    current

    For the investments made in manufacturing facilities to help import exports.

    Industry KPIs

    10
    MetricValueDetails
    Net price realization8.4%%
    Cigarette category share59.2%%
    Cigarette shipment volume-7.9%%
    Illicit trade enforcement70%%
    Smoke free market footprint7 marketsmarkets
    Smoke free consumer user countalmost 30Mconsumers
    Regulatory authorization pipelineMarketing Granted Orders
    Smoke free revenue and profitabilityprofitable
    Smoke free reduced risk shipment volumes>44M canscans
    Nicotine pouch oral tobacco category dynamics57%%

    Product announcements

    2
    ProductTypeDetails
    on! PLUS MINT, Wintergreen, and Tobaccolaunch
    FUMi brandexpansion

    Deals & partnerships

    1
    KT&GStrategic collaboration

    To advance international modern oral, U.S. non-nicotine growth, and traditional tobacco operating efficiencies.

    Capital programs

    1
    PM USA cigarette import and export capabilitiesunderway
    Period spend: $300M to $375M

    Benefit: Ability to participate in duty drawback; manufacturing center available for international markets; track and trace capabilities.

    Investments are the primary driver of elevated CapEx in 2026. These investments precede the volume and revenue from export, and provide capabilities for longer-term vision.

    Risks & headwinds

    6
    Widespread availability of illicit flavored disposable e-vapor productsOngoing

    Represented approximately 70% of the e-vapor category in 2025. Contributed 2-3% to cigarette industry decline over past 12 months.

    Mitigation: Advocating for stronger enforcement and acceleration of FDA market authorization. Early signs suggest efforts are beginning to impact the illicit marketplace, with growth in disposable e-vapor volumes and users moderating.

    Pace of FDA authorizationsOngoing

    Significant headwind.

    Mitigation: Encouraged by FDA's pilot program to streamline PMTA reviews for oral nicotine pouches. Hopeful for consistent enforcement and further improvements to regulatory process in 2026.

    Intellectual property landscapeOngoing

    Significant headwind.

    Mitigation: Maintaining a measured approach to investments in e-vapor until regulatory framework is functioning as intended.

    Competitive promotional activity in nicotine pouch categoryQ4 2025, ongoing

    Average retail prices for category competitors declined 3% sequentially and 12% year-over-year in Q4.

    Mitigation: Helix focused on balancing profitability with retaining loyal on! consumers, with on! prices increasing. on! PLUS is positioned as a premium differentiated product.

    Persistent discretionary income pressuresOngoing

    Primary driver of growth in the discount cigarette segment, which grew 2.6 share points in Q4 and 2.2 share points for FY25.

    Mitigation: Deploying Basic brand in ~30,000 stores to capture consumers who would otherwise go to deep discount, using revenue growth management analytics.

    Impairment charges on e-vapor assetsQ4 2025

    $1.3 billion noncash impairment charges.

    Mitigation: Believes valuable assets and capabilities from NJOY acquisition can be applied to future e-vapor pipeline. Maintaining measured approach to e-vapor investments.

    What to watch in Q1 FY26

    5

    Illicit e-vapor enforcement effectiveness

    next quarter
    CurrentGrowth in disposable e-vapor volumes moderated to 30% in 2025 (vs >50% in 2024), disposable vapor users to 10% (vs >40% in 2024).
    TargetContinued moderation or decline in illicit e-vapor volumes and user growth.

    Why it matters

    The pace of enforcement against illicit e-vapor products directly impacts the regulatory environment and Altria's investment strategy in the e-vapor category.

    Early signs suggest that these efforts, together with tariffs of Chinese manufactured goods, are beginning to impact the illicit marketplace. We are also seeing early indication that growth in the total number of disposable vapors is moderating.

    Q&A highlights

    7

    Clarification on the scope and nature of the import/export activity benefiting 2026 EPS outlook, and whether the elevated CapEx for this initiative is a one-time or multi-year increase.

    Management stated the import/export benefit is a mix of cost normalization and increased volume, but declined to provide specifics. They confirmed the elevated CapEx is primarily for import/export capabilities, which also supports their long-term vision, and while not guiding for future CapEx, they noted these investments generally precede volume and are disciplined.

    You are correct. The primary driver of the increase is the -- are the investments for our import export business. I'll repeat what Billy said, it not only provides us the ability to participate in the duty drawback, but it does provide us with capabilities for our longer-term vision.

    asked by Matthew Smith · answered by Salvatore Mancuso

    2 min read6 chapters

    Detailed Narrative

    01

    U.S. Nicotine Space Dynamics and Regulatory Environment

    The estimated number of adult consumers in e-vapor and oral tobacco categories grew to almost 30 million in 2025, nearly matching the adult smoker population. Smoke-free alternatives now represent over 50% of the total nicotine space, up 5 percentage points year-over-year. However, the growth is primarily driven by illicit flavored disposable e-vapor products, which represented approximately 70% of the e-vapor category in 2025. Altria advocates for stronger enforcement and accelerated FDA market authorizations to support tobacco harm reduction.

    02

    Progress in Nicotine Pouch Category

    Nicotine pouches continue to drive overall oral tobacco volume growth, increasing an estimated 14% over the past six months and now representing nearly 57% of the total oral category. Helix's on! brand grew reported shipment volume by approximately 11% to over 177 million cans for the full year 2025. The company is preparing for a national launch of on! PLUS in the first half of 2026, following FDA authorization for several variants, with early consumer feedback indicating strong differentiation in mouthfeel and flavor.

    03

    International Smoke-Free Expansion

    Altria is expanding its international smoke-free efforts, particularly in the fast-growing nicotine pouch category. The on!, on! PLUS, and newly added FUMi brands are competing across select international markets through e-commerce and targeted retail distribution. FUMi has expanded to 40,000 retail locations in 7 markets with 12 unique flavor offerings, generating valuable consumer insights for future product development and supporting long-term international smoke-free growth goals.

    04

    Smokeable Products Performance and Strategy

    The Smokeable Products segment delivered over $11 billion in adjusted OCI for the full year 2025, with margins expanding to 63.4%, driven by 8.4% net price realization. Domestic cigarette volumes declined by 10% for the full year. Marlboro's retail share declined, while Basic's retail share grew, reflecting PM USA's data-driven approach to compete in price-sensitive stores and capture consumers who might otherwise switch to deep discount brands. Management asserts that Basic's growth is not cannibalizing Marlboro.

    05

    Capital Allocation and Shareholder Returns

    Altria returned $8 billion to shareholders in 2025 through $7 billion in dividends and $1 billion in share repurchases. The Board raised the dividend by 3.9% in August, marking the 60th increase in 56 years. The company had $1 billion remaining under its $2 billion share repurchase program, which expires at the end of 2026. The balance sheet remains strong with a total debt-to-EBITDA ratio of 2x as of December 31, in line with its target.

    06

    E-Vapor Impairment and Future Approach

    Due to the slower-than-expected pace of effective enforcement against illicit e-vapor products, Altria recorded noncash impairment charges of $1.3 billion related to its e-vapor definite-lived intangible assets and goodwill in Q4 2025. The company intends to maintain a measured approach to e-vapor investments until the regulatory framework functions as intended and enforcement meaningfully addresses the illicit market, while still believing in the long-term potential of its NJOY assets.

    AI-generated summary of the company’s earnings call. Not investment advice.